

Title Page

Down-regulation of CYP1A2, CYP2B6, and CYP3A4 in human hepatocytes by prolyl hydroxylase domain 2 inhibitors via hypoxia-inducible factor- α stabilization

Hiroki Takano, Jun-ichi Yamaguchi, Sota Kato, Makoto Hamada, Mika Tada, and Hiromi Endo

Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan (H.T., J.Y., M.T., H.E.); Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan (S.K.); and Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan (M.H.)

Running Title Page

Running title: Down-regulation of CYP enzymes by PHD2 inhibitors

Corresponding author: Hiroki Takano, Drug Safety and Pharmacokinetics Laboratories,
Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Kita-ku, Saitama 331-9530, Japan. Tel:
+81-48-669-3097; Fax: +81-48-652-7254; E-mail: hir-takano@taisho.co.jp

Number of text pages: 48

Number of figures: 5

Number of tables: 3

Number of references: 30

Number of words in Abstract: 241

Number of words in Introduction: 747

Number of words in Discussion: 1451

Abbreviations: AhR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; CAR, constitutive androstane receptor; CHRM, cryopreserved hepatocytes

recovery medium; CYP, cytochrome P450; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immune sorbent assay; EPO, erythropoietin; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; G-6-P, glucose-6-phosphate; G-6-P-DH, glucose-6-phosphate dehydrogenase; HIF, hypoxia-inducible factor; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LDH, lactate dehydrogenase; MFI, median fluorescence intensity; NF- κ B, nuclear factor- κ B; PHD, prolyl hydroxylase domain; PXR, pregnane X receptor; RT, reverse transcription; RT-PCR, real-time polymerase chain reaction; RXR, retinoid X receptor; TBP, TATA box binding protein; WEM, Williams E medium.

Abstract

Hypoxia inducible factor (HIF) is associated with the expression of cytochrome P450 (CYP), but the underlying mechanism remains uncertain. In this study, we investigated the effect of HIF- α stabilization caused by novel prolyl hydroxylase domain (PHD) 2 inhibitors, which are HIF- α stabilizers that mimic hypoxia, on the expressions of CYP1A2, CYP2B6, and CYP3A4 in human hepatocytes. An mRNA expression analysis of human hepatocytes treated with PHD2 inhibitors for 72 h showed the down-regulation of genes encoding CYP1A2, CYP2B6, and CYP3A4. The mRNA repressions were accompanied with an increase in erythropoietin (EPO) protein, a marker of HIF- α stabilization, indicating that HIF- α stabilization was involved in the down-regulation of the CYP isoforms. To understand the underlying mechanisms, we assessed the relationship between the expressions of the CYP isoforms and those of their regulating transcription factors (aryl hydrocarbon receptor [AhR], AhR nuclear translocator [ARNT], constitutive androstane receptor [CAR], pregnane X receptor [PXR], and retinoid X receptor [RXR]) in human hepatocytes treated with the HIF- α stabilizers. As a result, the mRNA level of AhR did not decrease, though ARNT expression was repressed. On the other hand, the mRNA expression levels of CAR, PXR, and RXR were repressed and closely associated with those of CYP2B6 and CYP3A4. Although the underlying mechanism of the down-regulation for CYP1A2 remain unclear, the presently reported results suggest that the down-regulation of

CYP2B6 and CYP3A4 via HIF- α stabilization is caused by a decrease in the expressions of
CAR, PXR, and RXR.

Significance Statement

We showed that HIF- α stabilization down-regulates CYP1A2, CYP2B6, and CYP3A4 using PHD2 inhibitors, which are HIF- α stabilizers, as a new tool to mimic hypoxia in human hepatocytes. To understand the underlying mechanisms, we assessed the relationship between the expressions of the CYP isoforms and those of their regulating transcription factors. Our findings would contribute to a better understanding of the hypoxia-triggered regulatory mechanism of drug metabolizing enzymes in human hepatocytes.

Introduction

Several clinical trials in humans have demonstrated that hypoxemia in patients with cardiorespiratory diseases reduces the plasma clearance or prolongs the plasma half-life of some drugs, such as theophylline (Piafsky et al., 1977; Powell et al., 1978) and antipyrine (Cumming, 1976; Laybourn et al., 1986). Theophylline is primarily biotransformed by cytochrome P450 (CYP) 1A2 (Sarkar et al., 1992; Zhang et al., 1995) and antipyrine is metabolized by multiple CYP isoforms (Engel G et al., 1996). One of the mechanisms underlying the decrease in drug clearance is the alteration of hepatic CYP expression by hypoxia, as demonstrated by several experiments (Fradette et al., 2004; du Souich et al., 2011). For example, rabbits exposed to hypoxia resulted in the decreased protein expressions of CYP1A1, CYP1A2, CYP2B4, CYP2C5 and CYP2C16, and the increased protein expression of CYP3A6 in hepatocytes (Fradette et al., 2007). On the other hand, an *in vitro* study with HepaRG cells under severe hypoxia showed a decrease in the mRNA expressions of CYP1A2, CYP2C9, CYP3A4 and CYP2E1 (Legendre et al., 2009).

Hypoxia-inducible factor (HIF) has been regarded as the most important transcriptional factor activated by hypoxia (Mole et al., 2009; Semenza, 2011) and plays a central role in the regulation of many target genes involved in processes such as erythropoiesis, glucose

metabolism, and angiogenesis; furthermore, HIF is reportedly associated with the expressions of CYP isoforms. Effectively, the incubation of rabbit hepatocytes with CoCl_2 , a HIF- α (HIF-1 α and HIF-2 α unless otherwise noted) stabilizer used to mimic hypoxia, stabilized the expression of HIF-1 α , followed by an increased expression of *CYP3A6* genes by a mechanism in which both HIF-1 and activator protein-1 were implicated (Fradette et al., 2003). On the other hand, HepaRG cells incubated with desferrioxamine, another HIF- α stabilizer, down-regulated the genes of *CYP3A4* without the direct binding of HIF-1 α to a putative hypoxia response elements site in the 5'-flanking region of *CYP3A4* gene (Legendre et al., 2009). The different changes in CYP3A expression by the different putative mechanisms in the studies suggest that the HIF- α stabilization effect on CYP isoforms appears to be dependent on experimental conditions, such as experimental models, animal species, and the extent of hypoxia.

There is an increasing need to use human hepatocytes to elucidate the influence of HIF- α stabilization on CYP expression in humans, since human hepatocytes are recommended as an *in vitro* model to evaluate enzyme induction or down-regulation (EMA, 2012; PMDA, 2018; FDA, 2020). However, previous studies have not used human hepatocytes to evaluate the effect of HIF- α stabilization on the expressions of CYP isoforms. Moreover, the mechanism by which HIF- α stabilization down-regulates *CYP3A4* remains unknown.

Under normoxia conditions, cellular HIF- α is rapidly hydroxylated by HIF prolyl hydroxylase domain (PHD) enzymes (Jaakkola et al., 2001; Ivan et al., 2001), which are non-heme, iron-containing enzymes that hydroxylate the proline residues of HIF- α , leading to proteasomal degradation. Cobalt inhibits PHD enzymes by occupying an iron-binding site of the enzymes and the von Hippel-Lindau-binding domain of HIF- α (Yuan et al., 2003), resulting in HIF- α stabilization. Desferrioxamine is also known to stabilize HIF- α by chelating iron (Wang et al., 1993), since PHD enzymes require both oxygen and iron for hydroxylation process. Thus, CoCl_2 or desferrioxamine have been used for HIF- α stabilization to mimic hypoxia. However, as cobalt is a transition metal and desferrioxamine is an iron chelator, they might have some effects on other enzymes.

Recently, more attention has been paid to PHD2 inhibitors, since the pharmacological inhibition of PHD2, which leads to an increase in erythropoiesis, has therapeutic potential for patients with anemia associated with diseases in kidneys which play a critical role in erythropoiesis (Rabinowitz, 2013). Moreover, PHD2 inhibitors are also expected to be an effective tool for experimentally mimicking hypoxia conditions by stabilizing HIF- α and expected to be more suitable for evaluating the intrinsic effect of HIF- α stabilization on the expressions of CYP

isoforms than CoCl_2 or desferrioxamine.

The aim of this study was to elucidate the effects of HIF- α stabilization on the expressions of CYP isoforms in human hepatocytes and the mechanism of such effects, using PHD2 inhibitors as new tools to mimic hypoxia. We assessed the mRNA levels of CYP1A2, CYP2B6, and CYP3A4, which are regulated via different transcription factors, and the association of the expressions of CYP isoforms with erythropoietin (EPO) protein levels as a marker of HIF- α stabilization after exposure to PHD2 inhibitors. In addition, the mRNA expression levels of the transcription factors that regulate the expressions of the CYP isoforms were investigated to understand the underlying mechanisms.

Materials and Methods

Chemistry

All the PHD2 inhibitors (compounds 1–6, Table 1) were synthesized at Taisho Pharmaceutical (Saitama, Japan). The synthesis of the compounds is described in detail in the Supplemental Materials and Methods.

Preparation of human PHD2

Human PHD2 enzyme solution was obtained from Taisho Pharmaceutical (Saitama, Japan) as follows. Human PHD2 (NP_071334.1) was sub-cloned into pcDNA3.1/hygro (+) (Thermo Fisher Scientific, Waltham, MA) and the vector was transfected into 293FT cells. Then, the cells were harvested using a lysis buffer (20 mM Tris/HCl [pH7.5], 150 mM NaCl, 1 mM dithiothreitol, 0.1% Triton X-100, and proteinase inhibitor cocktail). The cell lysates were sonicated and centrifuged to prepare the enzyme solution.

Materials

Fluorescein isothiocyanate (FITC) HIF-1 α peptide was purchased from the PEPTIDE INSTITUTE (Osaka, Japan). 2-Oxoglutarate was purchased from Merck (Darmstadt, Germany).

Anti-hydroxylated HIF-1 α antibody was purchased from CST Japan (Tokyo, Japan). Cryopreserved hepatocytes recovery medium (CHRM), Williams E medium (WEM), fetal bovine serum, cell thawing/plating cocktail-A (Cocktail-A), Geltrex, cell maintenance cocktail-B (Cocktail-B), 10 mM dexamethasone, a QuantiGene Plex 2.0 Plex Set (12791, Human), a QuantiGene Plex 2.0 Assay Kit, a TaqMan Fast Cells-to-CT kit, and TaqMan q-PCR primer sets for CYP1A2, CYP2B6, CYP3A4, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (assay IDs: Hs00167927_m1 for CYP1A2 primer, Hs04183483_g1 for CYP2B6, Hs00604506_m1 for CYP3A4, and Hs02758991_g1 for GAPDH) were purchased from Thermo Fisher Scientific (Waltham, MA). Phenacetin was purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). Acetaminophen, bupropion, and testosterone were purchased from Sigma-Aldrich (St. Louis, MO). Hydroxybupropion and 6 β -hydroxytestosterone were purchased from Corning (Corning, NY). A Cell Counting Kit-8 was purchased from Dojindo Laboratories (Kumamoto, Japan). A lactate dehydrogenase (LDH) detection kit was obtained from Roche (Basel, Switzerland). An EPO enzyme-linked immune sorbent assay (ELISA) kit was purchased from STEMCELL Technologies (Vancouver, Canada). The deuterium-labeled internal standards for bioanalysis, hydroxybupropion-d₆ and 6 β -hydroxytestosterone-d₇, were purchased from Corning (Corning, NY), and *N*-(4-hydroxyphenyl-2,3,5,6-d₄)-acetamide was purchased from C/D/N Isotopes (Quebec,

Canada). All other chemicals and reagents were obtained from usual commercial sources, and were of the highest commercially available grades. The primary cultured cryopreserved human hepatocytes (Lot No. Hu8114, a 47-year-old Caucasian female) were purchased from Thermo Fisher Scientific (Waltham, MA). Pooled human liver microsomes (mixed gender, pool of 50 donors) were purchased from Sekisui XenoTech (Kansas City, KS).

Inhibitory activity of human PHD2

The PHD2 inhibition potentials of compounds 1–6 were evaluated using a PHD2 hydroxylation reaction known as a fluorescence polarization based assay with a FITC HIF-1 α peptide as a substrate. This method relies on the displacement of 2-oxoglutarate at the binding site by a competitive ligand. The incubation mixture consisted of 16 nM FITC HIF-1 α peptide, 1 ng/ μ L of lysates overexpressing human PHD2, 20 mM Tris-HCl buffer (pH7.5), 5 mM KCl, 1.5 mM MgCl₂, 10 μ M FeSO₄, 2 mM ascorbic acid, 1 mM dithiothreitol, 0.32 μ M 2-oxoglutarate, and one of several concentrations of compounds 1–6. A 20- μ L volume of the incubation mixture was incubated in 384-well plates in the dark at 30°C for 10 min. The reaction was stopped by the addition of 20 μ L of a stop solution containing anti-hydroxylated HIF1- α antibody, 20 mM EDTA, 100 mM Tris-HCl buffer (pH7.5), and 240 mM NaCl. The mixtures were well mixed, and the millipolarization values were measured at a 480-nm excitation and a 535-nm emission

using EnVision (PerkinElmer, Waltham, MA). The IC₅₀ values were calculated using XLfit version 5.3.0.8 (IDBS, Guildford, UK) and the nonlinear least squares method.

Cell cultures and compound treatments

The primary cultured cryopreserved human hepatocytes were thawed at 37°C and poured into CHRM. After centrifugation (100 xg, 10 min), the supernatant was discarded and the pellet was diluted at a density of 0.6×10^6 cells/mL with WEM containing 5% fetal bovine serum, 1 μM dexamethasone, and 3.6% Cocktail-A. Viability which was determined using trypan blue exclusion was more than 90%. The cell suspension solution was plated in collagen-coated 96-well plates (Corning, Corning, NY) at a volume of 125 μL/well. After the incubation for 4 to 6 h in a humidity atmosphere of 5% CO₂ at 37°C, the medium was removed, and the cells were overlaid with 0.35 mg/mL Geltrex in the support medium which was WEM containing 0.1 μM dexamethasone and 4% Cocktail-B. The medium was replaced with the support medium on the next day after the seeding. The plates were maintained in a humidity atmosphere of 5% CO₂ at 37°C for 3 days. Then, the cells were treated for approximately 72 h with one of the PHD2 inhibitors, omeprazole (50 μM, a positive control for CYP1A2 induction), phenobarbital (1000 μM, a positive control for CYP2B6 induction), rifampicin (10 μM, a positive control for CYP3A induction), tamoxifen (50 μM, a positive control for cell toxicity), or 0.1% dimethyl sulfoxide

(DMSO) as a vehicle control in the support medium; the final DMSO concentration in the support medium was 0.1% except for cell viability assay, in which the final DMSO concentration was 0.5%. The medium containing the test compounds or the vehicle control was replaced daily and the removed medium was stored at 4°C for the measurement of LDH levels or at from -40°C to -20°C for the measurement of EPO protein levels.

Evaluation of CYP enzyme activities

The enzyme activities of CYP1A2, CYP2B6, and CYP3A in human hepatocytes treated with compound 1 or positive controls (omeprazole, phenobarbital, or rifampicin) were measured. After the treatment of the compounds for 72 h in the condition described in the “Cell cultures and compound treatments” section, the cells were washed with the support medium two times, and then were incubated with 100 μM phenacetin for CYP1A2, 500 μM bupropion for CYP2B6, or 200 μM testosterone for CYP3A in the support medium at 37°C for 60 min. After the incubation period, a 50-μL aliquot of medium was removed from each well and was added to 100 μL of acetonitrile with 0.1% formic acid containing the internal standard (1.5 μM *N*-(4-hydroxyphenyl-2,3,5,6-d₄)-acetamide, 0.75 μM hydroxybupropion-d₆, or 5 μM 6β-hydroxytestosterone-d₇). The mixture was centrifuged for 10 min at 3974 xg, and the supernatant was subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) to

determine acetaminophen, hydroxybupropion, and 6 β -hydroxytestosterone, which were probe metabolites of phenacetin, bupropion, and testosterone, respectively.

Evaluation of CYP mRNA expression

The mRNA expression in human hepatocytes was analyzed using a real-time polymerase chain reaction (RT-PCR) method for compound 1 or using a QuantiGene Plex 2.0 assay for compounds 2–6.

(1) RT-PCR assay

The mRNA expression levels of CYP1A2, CYP2B6, CYP3A4, and the endogenous control GAPDH in human hepatocytes treated with compound 1 (1 and 10 μ M) were measured using an RT-PCR method. The RT-PCR was performed using the TaqMan Fast Cells-to-CT kit according to the manufacturer's instructions. Briefly, after the treatment of compound 1 for 72 h in the condition described in the "Cell cultures and compound treatments" section, the cells were lysed with lysis solution containing DNase I. The cell lysate was mixed with reverse transcription (RT) master mix containing RT buffer and RT enzyme. The mixture was incubated at 37°C for 60 min and subsequently at 95°C for 5 min to synthesize cDNA, and then kept at 4°C until use. The cDNA samples were mixed with each PCR cocktail including a PCR master mix and TaqMan probe in the PCR plate, and amplification was performed using the 7500 Fast

RT-PCR system (Thermo Fisher Scientific, Waltham, MA). The relative mRNA expressions were determined by dividing the mRNA expression of the target gene normalized to the *GAPDH* gene expression for the compound 1-treated wells by that of the vehicle control wells, which is known as the comparative cycle threshold ($\Delta\Delta C_T$) method.

(2) QuantiGene Plex 2.0 assay

The mRNA expression levels of CYP1A2, CYP2B6, CYP3A4, transcription factors (aryl hydrocarbon receptor [AhR], AhR nuclear translocator [ARNT], constitutive androstane receptor [CAR], pregnane X receptor [PXR], and retinoid X receptor [RXR]), and TATA box binding protein (TBP, an endogenous control) in human hepatocytes treated with one of the PHD2 inhibitors (compounds 2–5: 0.1, 1, or 10 μM ; compound 6: 0.3, 3, or 30 μM) were measured using a QuantiGene Plex 2.0 assay with the QuantiGene Plex 2.0 Plex Set and the QuantiGene Plex 2.0 Assay Kit according to the manufacturer's instructions. Briefly, after the treatment of compounds 2–6 for 72 h in the condition described in the “Cell cultures and compound treatments” section, the cells were lysed with a lysis mixture containing proteinase K. Then, the cell lysates were mixed with a lysis mixture containing proteinase K, blocking reagent, capture beads, and a 2.0 probe set designed to capture the target RNA molecules on the beads. The mixture was incubated at 54°C for 22 h for hybridization. After the hybridization, the signal amplification of the RNA samples was conducted using a stepwise reaction mediated by the

DNA amplification molecules. First, the beads were washed and incubated with the pre-amplifier solution at 50°C for 1 h. Next, the same procedure was conducted using the amplifier solution, followed by the label probe solution. Finally, the beads were washed and followed by the incubation with streptavidin phycoerythrin at room temperature for 30 min. The resulting fluorescence signal associated with individual capture beads was read on a Luminex 200 system (Luminex, Austin, TX) and was reported as the median fluorescence intensity (MFI). The MFI for each target gene was normalized to that of the *TBP* gene. The adjusted MFI values were used to determine the relative mRNA expression by dividing the average of the normalized MFI of the wells treated with the compounds 2–6 by that of the vehicle control wells.

Cell toxicity

Cell toxicity was evaluated according to cell viability for compound 1 and the release of LDH into the medium for compounds 2–6.

(1) Cell viability assay

The cell viability for compound 1 was measured at concentrations of 2.5, 5, 10, 20, 40, and 80 μ M using the Cell Counting Kit-8, according to the manufacturer's protocols. Briefly, after the treatment of compound 1 for 72 h in the condition described in the "Cell cultures and compound treatments" section, an aliquot of medium was removed from each well, followed by the

addition of Cell Counting Kit-8 (final, 10% v/v); the plate was then incubated in a humidity atmosphere of 5% CO₂ at 37°C for approximately 2 h. After the incubation, the absorbance at 450 nm with a reference at 650 nm was measured using a microplate spectrophotometer (Bio-Rad, Hercules, CA). Cell viability was calculated as follows: % viability = (mean absorbance in compound 1-treated well – blank well) / (mean absorbance in vehicle control well – blank well) × 100.

(2) LDH assay

The cellular toxicity was assessed by measuring LDH leakage into the culture medium. The LDH levels in the medium from hepatocytes treated with compounds 2–6 (compounds 2–5, 10 μM; compound 6, 30 μM) or tamoxifen (50 μM) was assayed using an LDH detection kit according to the manufacturer's instructions. Briefly, aliquots (30 μL) of the medium were added to 30 μL of the reaction mixture (Bottle 1/Bottle 2 = 1/45, v/v) in a 96-well plate, and the plate was incubated in the dark for 30 min at room temperature. After the incubation, the reaction was stopped by the addition of a volume of 25 μL of 1 M HCl. Then, the absorbance at 490 nm was measured using an ARVO SX (PerkinElmer, Waltham, MA). The cellular toxicity was evaluated based on the percentage of LDH released into the medium. Tamoxifen caused the release of almost all the LDH during 0 to 48 h because the LDH levels in the medium at 48 to 72 h was dramatically decreased, meaning that almost all the cells had died; thus, the total

amount of LDH released into the medium during 0 to 72 h after treatment with tamoxifen was regarded as being equivalent to 100% LDH in the cells.

Reversible inhibition of CYP enzymes

The incubation mixture (0.3 mL) consisted of 0.1 mg protein/mL human liver microsomes, 100 mM phosphate buffer (pH7.4), 99 mM KCl, 2.4 mM MgCl₂, 1.4 mM glucose-6-phosphate (G-6-P), 0.17 units/mL glucose-6-phosphate dehydrogenase (G-6-P-DH), each probe substrate (40 μM phenacetin for CYP1A2, 145 μM bupropion for CYP2B6, or 50 μM testosterone for CYP3A), and 10 μM of compound 1. After pre-incubation for 5 min, the reactions were initiated by the addition of a β-NADP⁺ solution (final, 0.15 mM). All incubations were conducted at 37°C for 10 min and were terminated by the addition of 0.3 mL of acetonitrile. After adding 30 μL of acetonitrile containing each internal standard (6 μM *N*-(4-hydroxyphenyl-2,3,5,6-d₄)-acetamide, 1.5 μM hydroxybupropion-d₆, or 20 μM 6β-hydroxytestosterone-d₇), the resultant precipitated proteins were removed by centrifugation at 3,974 xg for 10 min at 4°C to determine the probe metabolites using LC-MS/MS.

Time-dependent inhibition of CYP enzymes

Human liver microsomes were pre-incubated with compound 1 to allow for the generation of

intermediates that may inhibit CYP isoforms (1st incubation). After the 1st incubation, the aliquots of microsomes were transferred to the incubation mixtures containing probe substrates, and subsequent incubation was performed to measure the marker CYP activities (2nd incubation). The 1st incubation mixture (0.3 mL) consisted of 0.5 mg protein/mL human liver microsomes, 100 mM phosphate buffer (pH7.4), 98 mM KCl, 2.4 mM MgCl₂, 1.4 mM G-6-P, 0.17 units/mL G-6-P-DH, and compound 1 (10 μM). After pre-warming at 37°C for 5 min, the reaction for 0 or 30 min was initiated by the addition of distilled water or β-NADP⁺ (final, 0.15 mM), respectively. At 0 or 30 min after the initiation of the 1st incubation at 37°C, the aliquots of the 1st incubation mixtures (30 μL) were transferred to the 2nd incubation mixtures to initiate the incubation for each marker activity. The 2nd incubation mixture (0.3 mL) consisted of 0.05 mg protein/mL human liver microsomes, 91 mM phosphate buffer (pH7.4), 9.8 mM KCl, 2.2 mM MgCl₂, 1.3 mM G-6-P, 0.16 units/mL G-6-P-DH, 0.17 mM β-NADP⁺, and each probe substrate (200 μM phenacetin for CYP1A2, 700 μM bupropion for CYP2B6, or 250 μM testosterone for CYP3A). The 2nd incubation was conducted at 37°C for 10 min and was terminated by the addition of 0.3 mL of acetonitrile. After adding 30 μL of acetonitrile containing each internal standard (6 μM *N*-(4-hydroxyphenyl-2,3,5,6-d₄)-acetamide, 1.5 μM hydroxybupropion-d₆, or 20 μM 6β-hydroxytestosterone-d₇), the resultant precipitated proteins were removed by centrifugation at 3,974 xg for 10 min at 4°C to determine the probe

metabolites using LC-MS/MS.

Quantitative measurement of EPO

EPO protein levels in media of human hepatocytes treated with one of the PHD2 inhibitors were measured using a Human EPO ELISA Kit according to the manufacturer's instructions. First, the medium samples and the biotinylated anti-EPO antibodies were incubated in a 96-well microtiter plate pre-coated with an anti-EPO monoclonal capture antibody. Then, the wells were incubated with streptavidin-peroxidase conjugate, which bound to the biotinylated anti-EPO antibody. Finally, tetramethylbenzidine substrate solution was added, and color development was terminated after 15 min of incubation by the addition of the stop solution (0.5 M sulphuric acid). The color intensity was measured spectrophotometrically using a SpectraMax Plus384 (Molecular Devices, San Jose, CA) at 450 nm with 620 nm as a reference. The EPO protein concentration was totaled every 24 h to calculate the total EPO secretion over 72 h.

LC-MS/MS

An LC-MS/MS system consisting of an API4000 triple quadrupole mass spectrometer (AB SCIEX, Framingham, MA), an LC-20AD system (Shimadzu, Kyoto, Japan), and a CTC-PAL auto injector (CTC Analytics AG, Zwingen, Switzerland) were employed. The chromatographic

separations were performed on a Shimadzu Shim-pack XR-ODS column (2.2 μm , 30 \times 3.0 mm I.D., Shimadzu, Kyoto, Japan) at 50°C in a linear gradient elution mode with a mobile phase which consisted of a mixture of A (0.1% formic acid) and B (acetonitrile). The gradient conditions for elution of acetaminophen were as follows: 2% to 95% B (0.00–1.00 min); 98% B (1.00–1.20 min); 2% B (1.20 min). For hydroxybupropion, the gradient conditions were as follows: 2% to 60% B (0.00–1.00 min); 98% B (1.00–1.20 min); 2% B (1.20 min). The gradient conditions for 6 β -hydroxytestosterone were as follows: 2% to 40% B (0.00–1.60 min); 98% B (1.60–1.80 min); 2% B (1.80 min). Analyte concentrations were calculated from the ratio of the analyte peak area to the internal standard peak area, as interpreted from the calibration line using Analyst 1.6.1 software (AB SCIEX, Framingham, MA).

Statistical analysis

The statistical analysis of the data was performed using SAS version 9.2 (SAS Institute, Cary, NC) using Dunnett's multiple comparisons test to compare CYP mRNA expression or enzyme activity in human hepatocytes treated with PHD2 inhibitors with that in the control cells. *P* values of less than 0.05 were considered statistically significant.

Results

Inhibitory activity for PHD2

The PHD2 inhibitors used in this study were structurally diverse and were classified into two groups (Table 1): glycinamide (compounds 1–4) and triazolopyridine (compounds 5 and 6).

They showed inhibitory effects for human PHD2 with IC_{50} values ranging from 27 to 180 nM (Table 1). According to their IC_{50} values, the PHD2 inhibitors were divided into two groups as “weak inhibitors (compounds 3 and 4)” and “strong inhibitors (compounds 1, 2, 5, and 6).”

Effect of compound 1 on enzyme activities and mRNA expressions of CYP1A2, CYP2B6, and CYP3A in human hepatocytes

Enzyme activities of CYP1A2, CYP2B6, and CYP3A in hepatocytes were evaluated by measuring the probe metabolites in the medium; although the possible underestimation of total metabolite formation could not be ruled out due to no measurement of metabolites left in the cell pellet, the metabolites were measurable with enough levels to evaluate the CYP activities.

As demonstrated in Figure 1A, treatment with compound 1, a strong PHD2 inhibitor, in human hepatocytes for 72 h resulted in a dose-dependent decrease in the activities of CYP1A2, CYP2B6, and CYP3A. CYP1A2-dependent phenacetin O-deethylation, CYP2B6-dependent bupropion hydroxylation, and CYP3A-dependent testosterone 6 β -hydroxylation were decreased

by up to 82%, 71%, and 92%, compared with the vehicle control, at the highest concentration (10 μ M), respectively. On the other hand, the treatment of cultured human hepatocytes with positive control CYP inducers caused appropriate increases in CYP enzyme activity. Omeprazole (50 μ M), phenobarbital (1000 μ M), and rifampicin (10 μ M) caused increases of 40.3-fold, 33.5-fold, and 3.5-fold in the CYP1A2, CYP2B6, and CYP3A activities, respectively. In addition, an increasing dose of compound 1 reduced the mRNA expressions of CYP1A2, CYP2B6, and CYP3A4 (Figure 1B).

Cytotoxicity of the PHD2 inhibitors in human hepatocytes

The cytotoxicity of the PHD2 inhibitors in human hepatocytes was evaluated. The cellular morphology of the cells treated with the PHD2 inhibitors did not show cellular damage. Compound 1 exerted no toxic effects on cell viability at doses of up to 80 μ M after 72 h of exposure in human hepatocytes (Figure 2). In addition, as shown in Table 2, no obvious changes in LDH release during the 72 h after administration were observed in human hepatocytes treated with compounds 2–6, compared with that in the vehicle control. In contrast, LDH release from human hepatocytes with 50 μ M of tamoxifen, a positive control for cell toxicity, increased largely by as much as 66% during the first 24 h and 33% during 24 to 48 h, but thereafter decreased dramatically to 1% during 48 to 72 h, and the morphology of the cells treated with

tamoxifen showed massive cellular damage (data not shown).

Inhibitory effect of compound 1 on CYP1A2, CYP2B6, and CYP3A enzyme activities in both reversible and time-dependent inhibition

The inhibitory potential of compound 1 on CYP1A2, CYP2B6, and CYP3A activities was investigated to confirm that the observed decrease in activities of the CYP isoforms in human hepatocytes was independent of CYP enzyme inhibition. Human liver microsomes incubated with each CYP substrate in the presence or absence of compound 1 did not have an inhibitory effect on CYP1A2, CYP2B6, or CYP3A enzyme activities in both a reversible and time-dependent manner (Table 3).

Effect of the PHD2 inhibitors on CYP1A2, CYP2B6, and CYP3A4 mRNA expressions in human hepatocytes

To confirm whether the down-regulation of gene expression observed in compound 1 (Figure 1B) was associated with PHD2 inhibition as a class effect, the effects of the other structurally diverse PHD2 inhibitors on the mRNA expressions of CYP1A2, CYP2B6, and CYP3A4 were evaluated. The mRNA expression analysis of human hepatocytes treated with the PHD2 inhibitors (compounds 2–6) for 72 h showed a down-regulation of genes encoding CYP1A2,

CYP2B6, and CYP3A4, except for the effect of compound 4 on CYP3A4 mRNA (Figure 3). However, the degree and the dose dependency of the down-regulation differed between the weak PHD2 inhibitors (compounds 3 and 4) and the strong PHD2 inhibitors (compounds 2, 5, and 6). The CYP1A2 mRNA level was decreased by both the weak and the strong PHD2 inhibitors as the dose of inhibitor was increased. For both CYP2B6 and CYP3A4, the strong PHD2 inhibitors repressed the mRNA levels in a dose-dependent manner, although a clear dose-dependency was not observed with the weak PHD2 inhibitors.

Relationships of mRNA expressions of CYP1A2, CYP2B6, and CYP3A4 with EPO production in human hepatocytes treated with PHD2 inhibitors

We investigated the relationships between the mRNA expression levels of CYP1A2, CYP2B6, and CYP3A4 and the EPO protein levels in the media of human hepatocytes treated with the PHD2 inhibitors for 72 h. As demonstrated in Figures 4A and 4B, CYP1A2 mRNA repression was accompanied with an increase in the EPO levels for all the PHD2 inhibitors. On the other hand, the relationships of CYP2B6 and CYP3A4 expressions with EPO protein production differed between the strong and the weak PHD2 inhibitors. As shown in Figures 4C and 4E, the CYP2B6 and CYP3A4 expressions were repressed as the EPO levels increased in the presence of the strong PHD2 inhibitors (compounds 1, 2, 5, and 6), while these expressions were not

repressed EPO-dependently in the presence of the weak PHD2 inhibitors (compounds 3 and 4) in Figures 4D and 4F, although both the strong and the weak PHD2 inhibitors produced EPO. When compared at the same level of EPO production, the extent of CYP2B6 and CYP3A4 repression via the weak PHD2 inhibitors was smaller than that via the strong PHD2 inhibitors.

Correlations of mRNA repressions of CYP1A2, CYP2B6, and CYP3A4 with the levels of corresponding transcription factors in human hepatocytes treated with the PHD2 inhibitors

To understand the mechanism underlying the down-regulation of each CYP enzyme in human hepatocytes treated with the PHD2 inhibitors, we investigated the effect of the PHD2 inhibitors on the expressions of the transcription factors that regulate CYP1A2, CYP2B6, and CYP3A4 expressions. As the heterodimers of “AhR and ARNT”, “CAR and RXR”, and “PXR and RXR” are known to regulate the gene expressions of CYP1A2, CYP2B6, and CYP3A4, respectively, the correlations of mRNA expression between each CYP isoform and the corresponding transcription factor in human hepatocytes after exposure to the PHD2 inhibitors were assessed. The expression of AhR was not influenced by the PHD2 inhibitors (Figure 5A). On the other hand, the expressions of ARNT, CAR, PXR, and RXR were repressed to a minimum value of 0.655, 0.0986, 0.500, and 0.386 by compound 5 at 10 μ M, respectively (Figures 5B-5F). The

correlation coefficient (r) was calculated between the mRNA expression of each CYP isoform and that of the corresponding transcription factor. As a result, close correlations were observed between CYP1A2 and ARNT (Figure 5B, $r=0.84$), CYP2B6 and CAR (Figure 5C, $r=0.89$), CYP2B6 and RXR (Figure 5D, $r=0.87$), CYP3A4 and PXR (Figure 5E, $r=0.75$), and CYP3A4 and RXR (Figure 5F, $r=0.80$), while no correlation was observed between CYP1A2 and AhR (Figure 5A, $r=-0.10$).

Discussion

In this study, we investigated the effect of HIF- α stabilization on the expressions of CYP1A2, CYP2B6, and CYP3A4 in primary human hepatocytes using novel PHD2 inhibitors as the HIF- α stabilizers to mimic hypoxia. To understand their underlying mechanisms, moreover, our efforts were directed to elucidate the relationship between the expressions of the CYP isoforms and the transcription factors (AhR, ARNT, CAR, PXR, and RXR) that regulate the expressions of the CYP isoforms.

The PHD2 inhibitors used in this study were structurally diverse with two distinct motifs, glycinamide and triazolylpyridine, and were divided into “weak inhibitors” and “strong inhibitors” according to their IC₅₀ values. We showed that compound 1, a strong PHD2 inhibitor, reduced the activities of CYP1A2, CYP2B6, and CYP3A in human hepatocytes without inhibiting their enzyme activities. The decrease in CYP1A2, CYP2B6, and CYP3A activities was concomitant with the repression of their mRNA, indicating that the decrease in the expression levels of CYP1A2, CYP2B6, and CYP3A4 leads to the decrease in their activities. Further study demonstrated that the incubation of human hepatocytes with other PHD2 inhibitors also repressed the CYP1A2, CYP2B6, and CYP3A4 mRNA levels without causing any cellular damage, although the extent and the dose dependency of the repression caused by the weak PHD2 inhibitors were smaller than those caused by the strong PHD2 inhibitors. These

results suggest that the down-regulation of CYP enzymes is associated with HIF- α stabilization caused by the PHD2 inhibitors. To confirm the involvement of HIF- α stabilization, we showed that the decrease in CYP1A2, CYP2B6, and CYP3A4 mRNA was accompanied with an increase in EPO protein levels, a marker of HIF- α stabilization, when human hepatocytes were incubated with the PHD2 inhibitors. This supports the idea that the down-regulation of genes encoding CYP1A2, CYP2B6, and CYP3A4 is caused by HIF- α stabilization. In case of compound 5, the EPO levels at 1 μ M was higher than that at 10 μ M, despite a dose-dependent decrease in the mRNA expressions of CYP isoforms (Figures 4A, 4C, and 4E). As compound 5 is the strongest PHD2 inhibitor, the EPO production seems to reach maximum and flatten out between 1 and 10 μ M. Although the EPO levels associated with the weak PHD2 inhibitors were comparable to those associated with the strong PHD2 inhibitors, the weak inhibitors did not repress CYP2B6 or CYP3A4 to the same extent as the strong inhibitors. The reason for the reduced repression of CYP2B6 and CYP3A4 by the weak PHD2 inhibitors, despite the comparable EPO production, is poorly understood, but the different kinetics of HIF- α stabilization between the weak PHD2 inhibitors and the strong PHD2 inhibitors, and, in addition, the different mechanisms of down-regulation between CYP1A2 and CYP2B6/CYP3A4, as discussed in the next paragraphs, might be involved.

The mRNA expressions of CYP1A2, CYP2B6, and CYP3A4 are modulated by transcription factors, such as AhR, ARNT, CAR, PXR, and RXR (Rushmore et al., 2002). AhR binds to ARNT, and the heterodimer binds to xenobiotic response elements in the promoter regions of the *CYP1A2* gene, resulting in an increased formation of CYP1A2 mRNA. CAR and PXR respectively form a heterodimer with RXR, and the heterodimer activates the transcription of *CYP2B6* and *CYP3A4* by binding to the promoters, respectively. Thus, we investigated the effect of HIF- α stabilization on the expressions of transcription factors to clarify the underlying mechanism of the CYP down-regulation. The incubation of human hepatocytes with the PHD2 inhibitors did not alter the mRNA level of AhR, while repressed the ARNT mRNA expression. Although the mRNA expression of ARNT was closely correlated with that of CYP1A2, the repression of ARNT was weaker than that of CYP1A2. Therefore, it would be difficult to explain the repression of CYP1A2 solely by that of ARNT. Considering ARNT is heterodimerization partner for both HIF- α and AhR, a possible another mechanism is that an increase in the binding of stabilized HIF- α with ARNT could decrease the binding of AhR with ARNT, leading to a reduction of the transcription of *CYP1A2* gene (Chan et al., 1999). On the other hand, the mRNA expression of CAR, PXR, and RXR were repressed. The mRNA expressions of these transcription factors were closely correlated with those of CYP2B6 and CYP3A4. The repression of CAR was comparable to that of CYP2B6. Moreover, the combined repression of

PXR and RXR seemed to be comparable to the repression of CYP3A4, though each repression of PXR and RXR was weaker than that of CYP3A4. These results suggest that the decrease in CYP2B6 and CYP3A4 mRNA expression is probably caused by the repression of CAR, PXR, and RXR via an HIF- α -dependent mechanism, although the mechanism for the down-regulation of the transcription factors remains unknown.

A previous study conducted with HepaRG cells under hypoxia conditions (1% O₂ for 24 h) showed that severe hypoxia down-regulates the mRNA expressions of CYP1A2, CYP2C9, CYP3A4, CYP2E1, AhR, CAR, and PXR (Legendre et al., 2009). HepaRG is a highly differentiated cell line that displays many specific hepatocyte-like functions, including the activities of drug-metabolizing enzymes and transporters. Several studies have shown that HepaRG as well as human hepatocytes are valuable models for predicting the *in vivo* induction of CYP isoforms by drugs (Kanebratt et al., 2008; Vermet et al., 2016), suggesting that HepaRG has the same functions that regulate CYP enzymes via transcription factors as human hepatocytes. Our observations of a decrease in mRNA levels of CYP enzymes and transcription factors in human hepatocytes are very similar with previous observations (Legendre et al., 2009) in HepaRG, except for the results for AhR. AhR expression was repressed by hypoxia in the previous study (Legendre et al., 2009) but not by PHD2 inhibitors in the present study,

indicating that the hypoxia-induced decrease in AhR expression in HepaRG appears to be independent of HIF- α stabilization. Other factors that are not implicated in HIF- α stabilization but occur secondary to hypoxia might be involved in the repression of AhR. On the other hand, HIF-1 α stabilization in HepaRG treated with desferrioxamine down-regulates CYP3A4 expression without the direct binding of HIF-1 α to a putative hypoxia response elements site that is present in the 5'-flanking region of *CYP3A4* gene and had no effect on the luciferase activity of the *CYP3A4* 5'-flanking fragment (-1100/+11) (Legendre et al., 2009). The previous results do not conflict with our hypothesis that the down-regulation of PXR and RXR is involved in the repression of CYP3A4, since PXR response elements are located in the ~8 kb upstream of the transcription initiation site as well as a proximal promoter region (Goodwin et al., 1999).

Several other mechanisms have been reported to be involved in the regulation of the expressions of CYP enzymes by hypoxia. Hypoxia induces nuclear factor- κ B (NF- κ B) activity in HeLa cells (Oliver et al., 2009) and promotes the release of cytokines including IL-2, IL-4, IL-6, and IFN- γ in phytohemagglutinin-stimulated human peripheral mononuclear cells (Naldini et al., 1997). All these factors would also contribute to the repression of CYP during hypoxia. Indeed, acute moderate hypoxia in rabbits down-regulates CYP1A1, CYP1A2, CYP2B4, CYP2C5, and

CYP2C16 by increasing cytokines, such as IFN- γ , IL-1 β , and IL-2 (Fradette et al., 2007). In addition, the decrease in drug clearance associated with hypoxia in clinical is usually relevant to inflammation secondary to chronic obstructive lung disease, pneumonia or acute bronchitis. Inflammation also produces cytokines, which lead to the down-regulation of the CYP genes (Renton, 2004). Therefore, the clinical repercussions of HIF- α stabilization itself on CYP activity are difficult to evaluate separately from inflammation. In contrast, using PHD2 inhibitors *in vitro* could enable the contribution of HIF- α stabilization to CYP down-regulation to be evaluated separately from other factors, such as NF- κ B and cytokines produced by hypoxia or inflammation. Our results suggest that clinical HIF- α stabilization itself may reduce CYP1A2, CYP2B6, and CYP3A4 activities without the involvement of NF- κ B or cytokines, and thereby partially contributing to the decrease in drug clearance in patients with acute hypoxemia.

In conclusion, this is the first report to show that HIF- α stabilization down-regulates CYP1A2, CYP2B6, and CYP3A4 using PHD2 inhibitors, which act as specific HIF- α stabilizers, as a new tool to mimic hypoxia in human hepatocytes. Although the underlying mechanism of the down-regulation for CYP1A2 remains unclear, our results suggest that the decreases in the expressions of CAR, PXR and RXR lead to the down-regulation of CYP2B6 and CYP3A4

expressions via HIF- α stabilization. Our findings would contribute to a better understanding of the hypoxia-triggered regulatory mechanism of drug metabolizing enzymes in human hepatocytes. Additional studies are required to fully understand the mechanism underlying the down-regulation of transcription factors via HIF- α stabilization. Furthermore, the effects of the down-regulation of transcription factors on drug transporters or phase 2 drug metabolizing enzymes need to be evaluated to define the mechanism by which hypoxia affects drug clearance in greater detail.

Acknowledgments

We thank Mr. Takeshi Tani for useful discussions of the work described here. We also thank Mr.

Yoshiki Fukazawa for valuable suggestions on the manuscript.

Authorship Contributions

Participated in research design: Takano, Yamaguchi.

Conducted experiments: Takano, Kato, Tada.

Contributed new reagents or analytic tools: Hamada.

Performed data analysis: Takano, Kato, Tada.

Wrote or contributed to the writing of the manuscript: Takano, Yamaguchi, Kato, Hamada, Tada,

Endo.

References

Chan WK, Yao G, Gu YZ, and Bradfield CA (1999) Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. *J Biol Chem* **274**:12115-12123.

Cumming JF (1976) The effect of arterial oxygen tension on antipyrine half-time in plasma. *Clin Pharmacol Ther* **19**:468-471.

du Souich P and Fradette C (2011) The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression. *Expert Opin Drug Metab Toxicol* **7**:1083-1100.

Engel G, Hofmann U, Heidemann H, Cosme J, and Eichelbaum M (1996) Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. *Clin Pharmacol Ther* **59**:613-623.

European Medicines Agency (EMA) (2012) Guideline on the Investigation of Drug Interactions.

Committee for Human Medicinal Products (CHMP), London, UK.

Food and Drug Administration (FDA) (2020) In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions

Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Silver Spring, MD.

Fradette C and du Souich P (2003) Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia. *Br J Pharmacol* **140**:1146-1154.

Fradette C and du Souich P (2004) Effect of hypoxia on cytochrome P450 activity and expression. *Curr Drug Metab* **5**:257-271.

Fradette C, Batonga J, Teng S, Piquette-Miller M, and du Souich P (2007) Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver. *Drug Metab Dispos* **35**:765-771.

Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. *Mol Pharmacol* **56**:1329-1339.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr (2001) HIF α targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science* **292**:464-468.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ (2001) Targeting of HIF- α to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. *Science* **292**:468-472.

Kanebratt KP and Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. *Drug Metab Dispos* **36**:137-145.

Laybourn C, Tønnesen P, Loft S, Sonne J, and Døssing M (1986) Pulmonary disease and antipyrine clearance. *Clin Pharmacol Ther* **40**:415-419.

Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D, Lucas-Clerc C, Boudjema K, Guguen-Guillouzo C, Corlu A, and Morel F (2009) Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. *Eur J Cancer* **45**:2882-2892.

Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, and Ratcliffe PJ (2009) Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. *J Biol Chem* **284**:16767-16775.

Naldini A, Carraro F, Silvestri S, and Bocci V (1997) Hypoxia affects cytokine production and proliferative responses by human peripheral mononuclear cells. *J Cell Physiol* **173**:335-342.

Oliver KM, Garvey JF, Ng CT, Veale DJ, Fearon U, Cummins EP, and Taylor CT (2009) Hypoxia activates NF-kappaB-dependent gene expression through the canonical signaling pathway. *Antioxid Redox Signal* **11**:2057-2064.

Pharmaceuticals and Medical Devices Agency (PMDA) (2018) Guideline on drug interaction for drug development and appropriate provision of information. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

Piafsky KM, Sitar DS, and Rangno RE (1977) Theophylline kinetics in acute pulmonary edema. *Clin Pharmacol Ther* **21**:310-316.

Powell JR, Vozeh S, Hopewell P, Costello J, Sheiner LB, and Riegelman S (1978) Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. *Am Rev Respir Dis* **118**:229-238.

Rabinowitz MH (2013) Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. *J Med Chem* **56**:9369-9402.

Renton KW (2004) Cytochrome P450 regulation and drug biotransformation during inflammation and infection. *Curr Drug Metab* **5**:235-243.

Rushmore TH and Kong AN (2002) Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. *Curr Drug Metab* **3**:481-490.

Sarkar MA, Hunt C, Guzelian PS, and Karnes HT (1992) Characterization of human liver cytochromes P-450 involved in theophylline metabolism. *Drug Metab Dispos* **20**:31-37.

Semenza GL (2011) Oxygen sensing, homeostasis, and disease. *N Engl J Med* **365**:537- 547.

Vermet H, Raoust N, Ngo R, Esserméant L, Klieber S, Fabre G, and Boulenc X (2016) Evaluation of normalization methods to predict CYP3A4 induction in six fully characterized cryopreserved human hepatocyte preparations and HepaRG cells. *Drug Metab Dispos* **44**:50-60.

Wang GL and Semenza GL (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. *Blood* **82**:3610-3615.

Yuan Y, Hilliard G, Ferguson T, and Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia-inducible factor- α and von Hippel-Lindau protein by direct binding to

hypoxia-inducible factor-alpha. *J Biol Chem* **278**:15911-15916.

Zhang ZY and Kaminsky LS (1995) Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. *Biochem Pharmacol* **50**:205-211.

Footnotes

The authors in this work are all employees of Taisho Pharmaceutical Co., Ltd.

The authors received no outside funding for this work.

Figure Legends

Figure 1: Effect of compound 1 on enzyme activities (A) and mRNA expressions (B) of CYP1A2, CYP2B6, and CYP3A in human hepatocytes. Human hepatocytes were incubated with compound 1 or the vehicle control, which was replaced daily for 72 h. Data represent the mean \pm S.D. (n=3). Dunnett's multiple comparisons test was performed by comparing the compound 1-treated cells with the vehicle-treated cells (**, $p < 0.01$, ***, $p < 0.001$).

Figure 2: Cell viability after treatment with compound 1. Human hepatocytes were incubated with several concentrations of compound 1, which was replaced daily for 72 h. Cell viability was measured using the Cell Counting Kit-8. Data represent the mean \pm S.D. (n=4).

Figure 3: Effects of the PHD2 inhibitors on CYP1A2 (A), CYP2B6 (B), and CYP3A4 (C) mRNA expressions. Human hepatocytes were incubated with the PHD2 inhibitors (compounds 2–5: 0.1, 1, and 10 μ M; compound 6: 0.3, 3, and 30 μ M) or a vehicle control, which were replaced daily for 72 h. Data represent the mean \pm S.D. (n=3). The closed and open bars show the strong PHD2 inhibitors (compounds 2, 5, and 6) and weak PHD2 inhibitors (compounds 3 and 4), respectively. Dunnett's multiple comparisons test was performed by comparing the

PHD2 inhibitors-treated cells with the vehicle-treated cells (*, $p < 0.05$; **, $p < 0.01$, ***, $p < 0.001$).

Figure 4: Relationships of mRNA expressions of CYP1A2 (A and B), CYP2B6 (C and D), and CYP3A4 (E and F) with EPO production in human hepatocytes treated with the strong (A, C, and E) or weak (B, D, and F) PHD2 inhibitors. Compounds 1, 2, 5, and 6 are the strong PHD2 inhibitors. Compounds 3 and 4 are the weak PHD2 inhibitors. Human hepatocytes were incubated with the PHD2 inhibitors or a vehicle control, which were replaced daily for 72 h. The concentrations tested were as follows: 1 and 10 μM (compound 1); 0.1, 1, and 10 μM (compounds 2–5); and 0.3, 3, and 30 μM (compound 6). Data represent the mean \pm S.D. ($n=3$).

Figure 5: Correlations of mRNA expressions of CYP1A2, CYP2B6, and CYP3A4 with the corresponding transcription factors in human hepatocytes treated with the PHD2 inhibitors. Human hepatocytes were incubated with the individual PHD2 inhibitors (compounds 2–5: 0.1, 1, and 10 μM ; compound 6: 0.3, 3, and 30 μM), which were replaced daily for 72 h. The correlations between CYP1A2 and AhR (A), CYP1A2 and ARNT (B), CYP2B6 and CAR (C), CYP2B6 and RXR (D), CYP3A4 and PXR (E), and CYP3A4 and RXR (F) were analyzed. Data represent the mean ($n=3$). Lines represent the best-fit estimates of least-squares linear regression

analysis. A correlation coefficient (r) is shown for each plot.

Table 1: Structures of the PHD2 inhibitors and inhibitory activities for human PHD2

Compound	Structure	PHD2 inhibition IC ₅₀ (nM) ^a	IC ₅₀ value represents the mean of two experiments.
1		36	^a IC ₅₀ value represents the mean of two experiments.
2		39	
3		167	
4		180	
5		27	
6		64	

Table 2: LDH release after exposure to PHD2 inhibitors in human hepatocytes

Compound	Concentration (μ M)	LDH release (%) ^a		
		0–24 h	24–48 h	48–72 h
Control (0.1% DMSO)	-	3.9	2.9	1.7
2	10	3.7	3.0	2.5
3	10	3.0	2.0	2.5
4	10	3.6	2.0	1.9
5	10	3.7	5.7	6.3
6	30	3.2	2.0	2.9

^a Each value represents the mean (n=3). The total amount of LDH released into the medium for 72 h from cells treated with tamoxifen (50 μ M, a positive control for cell toxicity) was regarded as equivalent to 100% LDH in cells.


Table 3: Inhibitory effects of compound 1 (10 μ M) on CYP1A2, CYP2B6, and CYP3A enzyme activities in both reversible and time-dependent inhibitions in human microsomes

Mechanism	% inhibition ^a		
	CYP1A2	CYP2B6	CYP3A
Reversible inhibition	4.0	2.4	-3.2
Time-dependent inhibition ^b	-7.2	-2.3	-10.7

^a Each value represents the mean (n=3).

^b The time-dependent inhibition was indicated as the difference in the percent inhibition between with and without the 1st incubation.

(A) Enzyme activity



(B) mRNA expression




Figure 1






Figure 2

(A) CYP1A2



(B) CYP2B6



(C) CYP3A4




Figure 3






Figure 4


(A) CYP1A2-AhR




(B) CYP1A2-ARNT




(C) CYP2B6-CAR



(D) CYP2B6-RXR



(E) CYP3A4-PXR



(F) CYP3A4-RXR




Figure 5

DMD-AR-2020-000124R2

Supplemental Materials and Methods

Journal Title

Drug Metabolism and Disposition

Article Title

Down-regulation of CYP1A2, CYP2B6, and CYP3A4 in human hepatocytes by prolyl hydroxylase domain 2 inhibitors via hypoxia-inducible factor- α stabilization

Authors

Hiroki Takano, Jun-ichi Yamaguchi, Sota Kato, Makoto Hamada, Mika Tada, and Hiromi Endo

Abbreviations

APCI	Atmospheric pressure chemical ionization
DMSO	Dimethylsulfoxide
ESI	Electrospray ionization
$^1\text{H-NMR}$	Proton nuclear magnetic resonance
HPLC	High performance liquid chromatography
Me	Methyl
MS	Mass spectrum or mass spectrometry
δ	Chemical shift (ppm)
J	Coupling constant
s	Singlet
d	Doublet
t	Triplet
dd	Doublet of doublets
m	Multiplet
br	Broad
posi	Positive
nega	Negative


Synthesis of the compounds

All the solvents, materials, and reagents were used without purification after purchase. The $^1\text{H-NMR}$ spectra were recorded using Fourier transform type NMR (Varian Inova 300 or JOEL JNM-

ECA600). For analysis, ACD/SpecManager ver. 12.01 (trade name), ACD/Spectrum Processor™ and the like were used. Very subtle proton peaks, such as hydroxyl groups and amino groups, were not described. MS was measured using Agilent 6130. As the ionization method, a dual ionization method with the ESI method and the APCI method were used. The data listed are the actual values (found).

The synthesis of compound **1** was described in an earlier report (Hamada et al., 2018). Compounds **2**, **3**, and **4** were prepared in the same manner as compound **1**. The ¹H NMR spectra and MS data were as follows:

Compound 1




¹H NMR (600 MHz, CHLOROFORM-d) δ ppm 2.36 (s, 3 H) 2.54 - 2.67 (m, 2 H) 3.34 (t, J=7.2 Hz, 2 H) 4.15 - 4.21 (m, 2 H) 4.52 - 4.58 (m, 2 H) 6.84 - 6.90 (m, 1 H) 6.99 - 7.04 (m, 2 H) 7.17 - 7.22 (m, 2 H) 7.62 - 7.67 (m, 1 H) 8.10 (d, J=2.1 Hz, 1 H) 10.14 - 10.47 (m, 1 H).

MS ESI/APCI Dual posi: 412[M+H]⁺.

MS ESI/APCI Dual nega: 410[M-H]⁻.


Compound 2



¹H NMR (300 MHz, DMSO-d₆) δ ppm 3.08 - 3.28 (m, 2 H) 3.93 - 4.12 (m, 2 H) 4.45 (d, J=7.1 Hz, 2 H) 4.74 (d, J=7.1 Hz, 2 H) 5.01 - 5.18 (m, 2 H) 7.26 - 7.52 (m, 5 H) 7.57 - 7.71 (m, 4 H) 9.80 - 10.34 (m, 1 H) 12.89 (br s, 1 H).

MS ESI/APCI Dual posi: 423[M+H]⁺.

Compound 3




^1H NMR (300 MHz, DMSO-d_6) δ ppm 0.62 - 0.96 (m, 2 H) 1.03 - 1.31 (m, 2 H) 3.32 - 3.40 (m, 2 H) 3.98 - 4.08 (m, 2 H) 4.62 - 4.76 (m, 2 H) 7.45 - 7.56 (m, 2 H) 7.68 - 7.80 (m, 2 H) 10.01 - 10.42 (m, 1 H) 12.67 - 13.08 (m, 1 H).

MS ESI/APCI Dual posi: 399[M+H]⁺, 421[M+Na]⁺.

MS ESI/APCI Dual nega: 397[M-H]⁻.

Compound 4




^1H NMR (600 MHz, CHLOROFORM-d) δ ppm 2.57 - 2.71 (m, 2 H) 3.34 - 3.41 (m, 2 H) 4.15 - 4.23 (m, 2 H) 4.57 - 4.63 (m, 2 H) 7.18 - 7.24 (m, 1 H) 7.27 - 7.33 (m, 1 H) 7.37 - 7.41 (m, 1 H) 10.01 - 10.58 (m, 1 H).


MS ESI/APCI Dual nega: 421[M-H]⁻.

Compound 5

The synthetic route of compound **5** is shown below:



The details of the preparation of compound **5** were as follows.



Step 1-1

Methyl 6-chloro-4-methoxynicotinate (Lainchbury et al., 2012) (30.3 g), zinc cyanide (17.7 g), tetrakis(triphenylphosphine)palladium(0) (17.4 g), and *N,N*-dimethylformamide (150 mL) were mixed under an argon atmosphere. The mixture was stirred for 1 h at 100°C and cooled to room temperature. The mixture was diluted with ethyl acetate (600 mL) and water (600 mL) and filtered through a Celite® pad. The organic layer of the filtrate was separated, washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified using flash column chromatography (eluted with *n*-hexane:ethyl acetate = 9:1 to 1:1) to give methyl 6-cyano-4-methoxynicotinate (**SI-1**, 19.7 g) as a colorless solid.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 3.95 (s, 3 H) 4.03 (s, 3 H) 7.30 (s, 1 H) 8.94 (s, 1 H).

MS ESI/APCI Dual posi: 193[M+H]⁺.

Step 1-2

To a suspension of **SI-1** (6.50 g) in methanol (30 mL) was added a solution of sodium methoxide in methanol (approximately 28%, 580 mg), and the mixture was stirred for 30 min at 60°C. To the mixture were added formohydrazide (2.11 g) and acetic acid (120 mL). The mixture was refluxed for 30 min, cooled to room temperature, and concentrated under reduced pressure. The residue

was recrystallized from methanol to give methyl 4-methoxy-6-(1*H*-1,2,4-triazol-5-yl)pyridine-3-carboxylate (**SI-2**, 5.54 g) as a yellow solid.

ESI/APCI Dual posi: 235[M+H]⁺.

ESI/APCI Dual nega: 233[M-H]⁻.

Step 1-3

To a solution of **SI-2** (5.54 g) in methanol (70 mL) was added an aqueous solution of sodium hydroxide (1 mol/L, 70 mL). The mixture was stirred for 30 min at 60°C, cooled to room temperature, and concentrated under reduced pressure. The residue was diluted with water (50 mL). To the mixture was added hydrochloric acid (2 mol/L, 35 mL) slowly at 0°C. The precipitations were collected by filtration, washed with water and acetone, and dried under reduced pressure to give 4-methoxy-6-(1*H*-1,2,4-triazol-3-yl)pyridine-3-carboxylic acid (**SI-3**, 4.93 g) as a yellow solid.

¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 4.02 (s, 3 H) 7.78 (s, 1 H) 8.15 (br s., 1 H) 8.82 (s, 1 H).

MS ESI/APCI Dual posi: 221[M+H]⁺.

MS ESI/APCI Dual nega: 219[M-H]⁻.

Step 1-4

SI-3 (800 mg), 2-[6-(4-methoxyphenyl)-3-pyridinyl]-2-propanamine (Clements et al., 2010) (850 mg), *O*-(7-azabenzotriazol-1-yl)-*N,N,N,N*'-tetramethyluronium hexafluorophosphate (837 mg), and diisopropylethylamine (0.88 mL) were mixed in *N,N*-dimethylformamide (4.0 mL). The mixture was stirred for 3 h at 70°C and cooled to room temperature; water was then added. The mixture was extracted with chloroform three times. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified using HPLC (C18 column, 0.1% formic acid in water:0.1% formic acid in acetonitrile = 9:1 to 1:4) to give compound **5** (368 mg) as a colorless solid.


¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.73 (s, 6 H) 3.82 (s, 3 H) 4.10 (s, 3 H) 7.00 - 7.09 (m, 2 H) 7.80 (s, 1 H) 7.83 - 7.88 (m, 2 H) 7.99 - 8.08 (m, 2 H) 8.56 (br s, 1 H) 8.64 (s, 1 H) 8.68 - 8.73 (m, 1 H).

MS ESI/APCI Dual posi: 445[M+H]⁺.


MS ESI/APCI Dual nega: 443[M-H]⁻.

Compound 6

The synthetic route of compound **6** is shown below:



The details of the preparation of compound **6** were as follows.



Step 2-1

The reaction was performed in the same manner as step 1-2 using methyl 6-cyanopyridin-3-carboxylate (73.0 g) in place of **SI-1** to give methyl 6-(1H-1,2,4-triazol-5-yl)pyridine-3-carboxylate (**SI-4**, 75.6 g) as a yellow solid.

ESI/APCI Dual posi: 205[M+H]⁺.

Step 2-2

To a suspension of **SI-4** (75.6 g) in chloroform (740 mL) were added 3,4-dihydro-2H-pyran (170 mL) and *p*-toluenesulfonic acid monohydrate (3.52 g). The mixture was stirred for 4 h at 60°C, cooled to room temperature, and poured into a saturated aqueous solution of sodium hydrogen carbonate. The organic layer was separated, and the aqueous layer was extracted with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. To the residue was added diisopropyl ether (500 mL). The mixture was stirred for 1 h at 0°C and the precipitations were collected by filtration. The crude product was recrystallized from ethyl acetate to give methyl 6-[1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-3-yl]pyridine-3-carboxylate (**SI-5**, 83.3 g) as a light brown solid.

¹H NMR (300 MHz, CHLOROFORM-*d*) δ ppm 1.61 - 1.83 (m, 3 H) 1.97 - 2.19 (m, 2 H) 2.20 - 2.30 (m, 1 H) 3.69 - 3.81 (m, 1 H) 3.98 (s, 3 H) 4.08 - 4.18 (m, 1 H) 5.58 (dd, J=9.2, 2.8 Hz, 1 H)

8.25 (dd, J=8.2, 0.8 Hz, 1 H) 8.35 - 8.46 (m, 2 H) 9.32 (dd, J=2.2, 0.8 Hz, 1 H).

MS ESI/APCI Dual posi: 289[M+H]⁺.

Step 2-3

The reaction was performed in the same manner as step 1-3 using **SI-5** (25.8 g) in place of **SI-2** to give a mixture containing 6-[1-(tetrahydro-2H-pyran-2-yl)-1H-1,2,4-triazol-3-yl]pyridine-3-carboxylic acid (**SI-6**, 30.7 g) as a light brown solid.

¹H NMR (300 MHz, D₂O) δ ppm 1.62 - 1.86 (m, 3 H) 1.98 - 2.29 (m, 3 H) 3.77 - 3.89 (m, 1 H) 4.02 - 4.13 (m, 1 H) 5.68 (dd, J=9.1, 3.3 Hz, 1 H) 8.03 (d, J=8.2 Hz, 1 H) 8.32 (dd, J=8.2, 2.1 Hz, 1 H) 8.70 (s, 1 H) 9.02 (d, J=1.9 Hz, 1 H).

MS ESI/APCI Dual posi: 275[M+H]⁺.

MS ESI/APCI Dual nega: 273[M-H]⁻.

Step 2-4

SI-6 (5.00 g), amine (2.92 g), trimethylamine (3.2 mL), and 1-hydroxybanztriazole monohydrate (3.45 g) were mixed in chloroform (60 mL). To the mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.32 g). The mixture was stirred for 1 h at 60°C and cooled to room temperature; a saturated aqueous solution of sodium hydrogen carbonate was then added, and the compound was extracted with chloroform twice. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was solidified from ethyl acetate to give a mixture containing protected **6** (5.48 g) as an off-white solid. To the suspension of the protected **6** (5.48 g) in methanol (80 mL) were added water (40 mL) and trifluoroacetic acid (20 mL). The mixture was stirred for 1 h at 60°C, cooled to room temperature, and concentrated under reduced pressure. The residue was purified using HPLC (C18 column, 0.1% formic acid in water:0.1% formic acid in acetonitrile = 9:1 to 1:4) to give **6** (3.16 g) as a colorless solid.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 3.15 (t, J=8.7 Hz, 2 H) 4.34 - 4.61 (m, 4 H) 6.71 (d, J=8.2 Hz, 1 H) 7.08 (dd, J=8.1, 1.9 Hz, 1 H) 7.23 (d, J=1.1 Hz, 1 H) 8.18 (dd, J=8.2, 0.8 Hz, 1 H) 8.26 - 8.51 (m, 2 H) 9.13 (dd, J=2.2, 0.8 Hz, 1 H) 9.25 (t, J=5.8 Hz, 1 H).

MS ESI/APCI Dual posi: 322[M+H]⁺.

MS ESI/APCI Dual nega: 320[M-H]⁻.

References

Hamada M, Takayama T, Shibata T, Hiratate A, Takahashi M, Yashiro M, Takayama N, Okumura-Kitajima L, Koretsune H, Kajiyama H, Naruse T, Kato S, Takano H, and Kakinuma H (2018) Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid

derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia. *Bioorg Med Chem Lett* **28**:1725-1730.

Lainchbury M, Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Garrett MD, and Collins I (2012) Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. *J Med Chem* **55**:10229-10240.

Clements MJ, Debenham JS, Hale JJ, and Madsen-Duggan C (2010) inventors, Merck Sharp & Dohme Corp., assignee. Substituted 4-hydroxypyrimidine-5-carboxamides. WO2011002624A1. 2011 Jan 6.